da

DA-3003-1 (DA-3003-1) 是一种可渗透进细胞膜且具有有效性和选择性的 Cdc25 dual specificity phosphatase 抑制剂，具有抗肿瘤活性，对 Cdc25B2、Cdc25A、Cdc25B2 和 Cdc25C具有抑制作用。

DA-6886 是一种 5-羟色胺受体 4（5-HT4）激动剂。DA-6886 以 5-HT4 受体拮抗剂敏感的方式诱导大鼠食道制剂松弛。在表达 hERG 通道的 CHO 细胞中对 DA-6886 进行的评估显示，它抑制 hERG 通道电流的 pIC50 值为 4.3，表明该化合物对 5-HT4 受体的选择性比 hERG 通道高 1000 倍。

Dmt-2'fluoro-da(bz) amidite 是一种 2'-脱氧-2'-氟代硫代磷酸酯寡核苷酸，对 RNA 靶标具有很高的亲和力和特异性。Dmt-2'fluoro-da(bz) amidite 也是 5'-DMT-3'-亚磷酰胺合成的中间体，是抗核酸酶的反义化合物。

DA-143主要作用为选择性抑制DNA-PKcs，其IC50值仅为2.5 nM，显示出优异的选择性。相比之下，对mTOR、PI3KΔ和ATM的IC50值分别为280 nM、106 nM和6,594 nM。此外，DA-143能有效抑制DNA-PKcs底物的磷酸化过程，从而增强癌细胞对阿霉素的敏感性。

DA-8031为一种具有口服活性的选择性血清素再摄取抑制剂，主要用于早泄(PE)相关研究。

DA-0157 是一种口服活性的 EGFR 和 ALK 抑制剂，能够克服非小细胞肺癌（NSCLC）中 EGFR 和 ALK 的耐药突变。其能够抑制 Ba F3-EGFR Del19 T790M C797S（IC50= 6.9 nM）、Ba F3-EGFR WT（IC50= 0.83 μM）、Ba F3-EML4-ALK-L1196M（IC50= 5.5 nM）和 Ba F3-EML4-ALK（IC50= 7.4 nM）的增殖，并且抑制 CYP2D6，IC50 为 5.26 μM。在小鼠模型中，DA-0157 展示了抗肿瘤活性。

DA-1241 是一种 GPR119 激动剂。通过活化 GPR119，DA-1241 能下调 NFκB 信号，进而抑制巨噬细胞的分化。无论是单独使用还是与 DPP4 抑制剂联合使用，DA-1241 都可以减轻肝脏炎症，同时恢复与炎症相关的肝脏基因表达。DA-1241 适用于研究代谢功能障碍相关脂肪性肝炎 (MASH)。

DA-302168S 是一种口服有效的选择性 GLP-1R 激动剂，EC50 值为 1.32 nM。它能刺激胰岛素分泌，具有降血糖效果，并能减少食物摄入。该化合物主要激活猴和人的 GLP-1R，而对大鼠、小鼠和犬的 GLP-1R 几乎没有激动作用。DA-302168S 可用于 2 型糖尿病和肥胖症研究。

DA 1131 is a new carbapenem antibiotic. It undergoes renal metabolism by renal dehydropeptidase I.

DA 1686是一种治疗性抗心律失常的化合物。DA 1686可以降低乌头碱引起的心动过速作用。它也可以降低电刺激频率增加的影响并且其活性是奎尼丁的1.8倍，是普鲁卡因胺的9倍。

DA 4360 is an H2-receptor antagonist. The compounds which were investigated in a wider concentration range, behaved as simple competitive antagonists, yielding apparent KB values comparable with those estimated in conventional H2-receptor assays.

DA 4626 is H2-receptor antagonism. The compound which was investigated in a wider concentration range, behaved as simple competitive antagonists, yielding apparent KB values comparable with those estimated in conventional H2-receptor assays.

DA 5018 is a capsaicin derivative and is also a new non-narcotic analgesic. It has an antipruritic effect.

DA-11004 is a potent NADP-dependent isocitrate dehydrogenase inhibitor (IC50: 1.49 μM for IDPc). DA-11004 inhibited fatty acid synthesis in adipose tissues via IDPc inhibition. It also decreased the plasma glucose levels and FFA in HF diet-induced obesity

DA-3934 has a high affinity for gastrin/CCK-B receptors and high selectivity over CCK-A receptors. DA-3934 and its methyl ester derivative inhibited pentagastrin-induced gastric acid secretion in rats in a dose-dependent manner.

DA-7867 is a novel oxazolidinone. DA-7867 had the lowest MIC for 90% of the aerobic gram-positive bacterial strains tested (≤0.25 μg ml) and it was more potent than linezolid. DA-7867 was the most active drug with a MIC(90) of 0.125 μg ml.

DA-E 5090 is a pharmacologically active metabolite of E 5090, is an interleukin-1 antagonist. DA-E 5090 is a novel inhibitor of IL-1 generation, in vitro inhibitory effects on the generation of IL-1 by human monocytes.

DA 3505 is one of feprazone metabolite. Limits of detection are 0.1 microgram feprazone per ml plasma and 0.2 microgram of its metabolite per ml plasma using the HPLC method. Concentration down to about 0.5 microgram/ml plasma of both compounds can be det

5’-O-DMT-PAC-dA can be used in the synthesis of oligoribonucleotides[1]. [1]. Schulhof JC, et, al. The final deprotection step in oligonucleotide synthesis is reduced to a mild and rapid ammonia treatment by using labile base-protecting groups. Nucleic Acids Res. 1987 Jan 26;15(2):397-416.

5’-O-TBDMS-Bz-dA is a nucleoside with protective and modification effects.

5’-O-TBDMS-dA is a modified nucleoside and can be used to synthesize DNA or RNA.

DA-JC4 is a compound with dual GLP-1 GIP receptor agonist properties. It is recommended for use in researching neurological diseases and investigating insulin signaling pathways[1][2][3].

Ac-dA Phosphoramidite is a phosphinamide monomer utilized for oligonucleotide synthesis.

N6-Methyl-dA phosphoramidite can be used in the synthesis of oligodeoxyribonucleotides.